Free Access
Neuroepidemiology 2008;30:254–265

Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer’s Disease


Visser P.J.a, b · Verhey F.R.J.a · Boada M.d · Bullock R.e · De Deyn P.P.h · Frisoni G.B.i · Frölich L.k · Hampel H.l-n · Jolles J.a · Jones R.f · Minthon L.o · Nobili F.j · Olde Rikkert M.c · Ousset P.-J.q · Rigaud A.-S.r · Scheltens P.b · Soininen H.t · Spiru L.u · Touchon J.s · Tsolaki M.v · Vellas B.q · Wahlund L.-O.p · Wilcock G.g · Winblad B.p
aDepartment of Psychiatry and Neuropsychology, University of Maastricht, Maastricht, bDepartment of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, and cDepartment of Geriatrics, Radboud University Medical Centre, Nijmegen, The Netherlands; dFundació ACE, Barcelona, Spain; eKingshill Research Centre, Swindon, fThe Research Institute for the Care of Older People, Bath, and gDepartment of Care of Elderly, University of Bristol, Frenchay Hospital, Bristol, UK; hInstitute Born Bunge, ZNA Middelheim, University of Antwerp, Antwerp, Belgium; iLENITEM, IRCCS Fatebenefratelli, Brescia, and jClinical Neurophysiology Service Unit, Department of Endocrinological and Metabolic Sciences, University of Genoa, Genoa, Italy; kDivision of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit, University of Heidelberg, Mannheim, and lAlzheimer Memorial Centre and Geriatric Psychiatry Branch, Dementia and Neuroimaging Section Department of Psychiatry, Ludwig-Maximilian University, Munich, Germany; mDiscipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Trinity Centre for Health Sciences, and nThe Adelaide and Meath Hospital Incorporating The National Children’s Hospital, Dublin, Ireland; oClinical Memory Research Unit, Department of Clinical Sciences Malmö Lund University, Lund, and pNVS Department, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden; qDepartment of Internal Medicine and Clinical Gerontology, Toulouse University Hospital, Toulouse, rDepartment of Geriatrics, Hopital Broca, Paris, and sInstitute National de la Santé et de la Recherche Medicinale INSERM U 888, Montpellier, France; tDepartment of Neurology, University and University Hospital of Kuopio, Kuopio, Finland; u‘Carol Davila’ University of Medicine and Pharmacy, Bucharest, Romania; vAristotle University of Thessaloniki, Memory and Dementia Centre, G. Papanicolaore General Hospital, Thessaloniki, Greece
email Corresponding Author

 goto top of outline Key Words

  • Alzheimer’s disease, diagnosis
  • Mild cognitive impairment, elderly
  • Study, longitudinal cohort, observational, multicentre

 goto top of outline Abstract

Background: There is an urgent need to identify subjects with Alzheimer’s disease (AD) in the predementia phase, but validated diagnostic approaches are currently lacking. In this paper, we present the background, design and methods of a study, which aims to develop clinical criteria for predementia AD. We also present baseline characteristics of the subjects included. The study was part of the multicentre DESCRIPA project, which is being conducted within the network of the European Alzheimer’s Disease Consortium. Methods: Clinical criteria will be based on a prospective cohort study of non-demented subjects older than 55 years and referred to a memory clinic. At baseline, a number of markers and risk factors for AD were collected, including demographic variables, measures of performance in activities of daily living, cognitive, neuroimaging and genetic markers, and serum and cerebrospinal fluid markers. Subjects will be reassessed annually for 2–3 years, and we will evaluate which combination of variables best predicts AD-type dementia at follow-up. Results: Between 2003 and 2005, 881 subjects were included from 20 memory clinics. Subjects were on average 70.3 years old, and had 10.4 years of education. The average score on the Mini-Mental State Examination was 27.4.

Copyright © 2008 S. Karger AG, Basel

 goto top of outline References
  1. Ott A, Breteler M, van Harskamp F, Claus J, van der Cammen T, Grobbee D, Hofman A: Prevalence of Alzheimer’s disease and vascular dementia: association with education. The Rotterdam Study. BMJ 1995;310:970–973.
  2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work-Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–944.
  3. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–746.
  4. Visser P: Mild cognitive impairment; in Pathy MSJ, Morley JE, Sinclair A (eds): Principles and Practice of Geriatric Medicine. London, John Wiley & Sons, 2006, pp 1095–1103.
  5. Visser PJ, Verhey FRJ, Scheltens P, Cruts M, Ponds RWHM, Hofman PAM, Van Broeckhoven CM, Jolles J: Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects. J Neurol 2002;249:312–319.
  6. Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ: Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007;68:828–836.
  7. Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ: Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2007;68:1588–1595.
  8. Wilson RS, Bennett DA, Bienias JL, Mendes de Leon CF, Morris MC, Evans DA: Cognitive activity and cognitive decline in a biracial community population. Neurology 2003;61:812–816.
  9. Folstein MF, Folstein SE, McHugh PR: ‘Mini-Mental State’, a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  10. Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and of senile changes in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797–811.
  11. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179–186.
  12. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW: Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914–919.
  13. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33–S39.
  14. Hindmarch I, Lehfeld H, de Jongh P, Erzigkeit H: The Bayer Activities of Daily Living Scale (B-ADL). Dement Geriatr Cogn Disord 1998;9(suppl 2):20–26.
  15. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K: Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996;25:113–120.
  16. Mahoney FI, Barthel DW: Functional evaluation: the Barthel Index. Md State Med J 1965;14:61–65.
  17. Cummings JL: The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48:S10–S16.
  18. Reisberg B, Auer SR, Monteiro IM: Behavioral pathology in Alzheimer’s disease (BEHAVE-AD) rating scale. Int Psychogeriatr 1996;8(suppl 3):301–308, discussion 351–354.

    External Resources

  19. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
  20. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389.
  21. Sheikh J, Yesavage J: Geriatric Depression Scale (GDS): recent evidence and development of a shorter version; in Brink TL (ed): Clinical Gerontology: A Guide to Assessment and Intervention. New York, Haworth Press, 1986, pp 165–173.
  22. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA: Cornell Scale for Depression in Dementia. Biol Psychiatry 1988;23:271–284.
  23. Radloff L: The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385–401.

    External Resources

  24. Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW: The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson’s disease. Int J Geriatr Psychiatry 2000;15:644–649.
  25. Malakouti SK, Fatollahi P, Mirabzadeh A, Salavati M, Zandi T: Reliability, validity and factor structure of the GDS-15 in Iranian elderly. Int J Geriatr Psychiatry 2006;21:588–593.
  26. Haringsma R, Engels GI, Beekman AT, Spinhoven P: The criterion validity of the Center for Epidemiological Studies Depression Scale (CES-D) in a sample of self-referred elders with depressive symptomatology. Int J Geriatr Psychiatry 2004;19:558–563.
  27. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J: Atrophy of medial temporal lobes on MRI in ‘probable’ Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967–972.
  28. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P: A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318–1322.
  29. Brandt J, Spencer M, Folstein M: The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol 1988;1:111–117.
  30. APA: Diagnostic and Statistical Manual of Mental Disorders. Washington, American Psychiatric Association, 1994.
  31. Roman GC, Tatemichi TK, Erkinjuntti T, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS- AIREN international workshop. Neurology 1993;43:250–260.
  32. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–1124.
  33. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–1554.
  34. Visser PJ, Kester A, Jolles J, Verhey F: Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006;67:1201–1207.
  35. Oostenbrink R, Moons KG, Donders AR, Grobbee DE, Moll HA: Prediction of bacterial meningitis in children with meningeal signs: reduction of lumbar punctures. Acta Paediatr 2001;90:611–617.
  36. Altman DG: Practical Statistics for Medical Research. London, Chapman & Hall, 1995.
  37. Steyerberg EW, Eijkemans MJ, Harrell FE Jr, Habbema JD: Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 2000;19:1059–1079.
  38. Visser PJ, Verhey FRJ, Ponds RWHM, Jolles J: Characteristics of preclinical Alzheimer’s disease. Int J Geriatr Psychiatry 2002;17:88–89.
  39. Visser PJ, Scheltens P, Verhey FR: Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer’s disease? J Neurol Neurosurg Psychiatry 2005;76:1348–1354.
  40. Dickerson BC, Sperling RA, Hyman BT, Albert MS, Blacker D: Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry 2007;64:1443–1450.
  41. Robert PH, Berr C, Volteau M, Bertogliati C, Benoit M, Mahieux F, Legrain S, Dubois B: Neuropsychological performance in mild cognitive impairment with and without apathy. Dement Geriatr Cogn Disord 2006;21:192–197.
  42. Perri R, Serra L, Carlesimo GA, Caltagirone C: Preclinical dementia: an Italian multicentre study on amnestic mild cognitive impairment. Dement Geriatr Cogn Disord 2007;23:289–300.
  43. Feldman H, Levy AR, Hsiung GY, Peters KR, Donald A, Black SE, Bouchard RW, Gauthier SG, Guzman DA, Hogan DB, Kertesz A, Rockwood K: A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. Neuroepidemiology 2003;22:265–274.
  44. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Toga AW, Beckett L: The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin N Am 2005;15:869–877, xi–xii.
  45. Grundman M, Petersen RC, Bennett DA, Feldman HH, Salloway S, Visser PJ, Thal LJ, Schenk D, Khachaturian Z, Thies W, Alzheimer’s Association Research Roundtable: Alzheimer’s Association Research Roundtable meeting on mild cognitive impairment: What have we learned? Alzheimers Dement 2006;2:393–414.

    External Resources

  46. Jelic V, Kivipelto M, Winblad B: Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry 2006;77:429–438.
  47. Stokholm J, Jakobsen O, Czarna JM, Mortensen HV, Waldemar G: Years of severe and isolated amnesia can precede the development of dementia in early-onset Alzheimer’s disease. Neurocase 2005;11:48–55.
  48. Hodges JR, Erzinclioglu S, Patterson K: Evolution of cognitive deficits and conversion to dementia in patients with mild cognitive impairment: a very-long-term follow-up study. Dement Geriatr Cogn Disord 2006;21:380–391.
  49. Lezak M. Neuropsychological Assessment. New York, Oxford University Press, 1995.
  50. Van der Elst W, van Boxtel MP, van Breukelen GJ, Jolles J: Rey’s verbal learning test: normative data for 1,855 healthy participants aged 24–81 years and the influence of age, sex, education, and mode of presentation. J Int Neuropsychol Soc 2005;11:290–302.
  51. de Rotrou J, Wenisch E, Chausson C, Dray F, Faucounau V, Rigaud AS: Accidental MCI in healthy subjects: a prospective longitudinal study. Eur J Neurol 2005;12:879–885.
  52. Carlesimo GA, Caltagirone C, Gainotti G: The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 1996;36:378–384.
  53. Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). V. A normative study of the neuropsychological battery. Neurology 1994;44:609–614.
  54. Aebi C. Validierung der neuropsychologischen Testbatterie CERAD-NP. Basel, Universität Basel, 2002.
  55. Hänninen T, Pulliainen V, Salo J, Hokkanen L, Erkinjuntti T, Koivisto K, Viramo P, Soininen H: Kognitiiviset testit muistihäiriöiden ja alkavan dementian varhaisdiagnostiikassa: CERAD-tehtäväsarja. Suomen Lääkärilehti 1999;54:1967–1975.
  56. Brandt J: The Hopkins verbal learning test: development of a new memory test with six equivalent forms. The Clinical Neuropsychologist 1991;5:125–142.
  57. Benedict RHB, Schretlen D, Groninger L, Brandt J: Hopkins verbal learning test-revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 1998;12:43–55.

    External Resources

  58. Grober E, Buschke H, Crystal H, Bang S, Dresner R: Screening for dementia by memory testing. Neurology 1988;38:900–903.
  59. Van der Linden M: L’évaluation des troubles de la mémoire: présentation de quatre tests de mémoire épisodique. Marseille, Editions Solal, 2004.
  60. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364.
  61. Masur DM, Fuld PA, Blau AD, Thal LJ, Levin HS, Aronson MK: Distinguishing normal and demented elderly with the selective reminding test. J Clin Exp Neuropsychol 1989;11:615–630.
  62. Wechsler D: Wechsler Memory Scale – 3rd edition: Administration and Scoring Manual. San Antonio, The Psychological Corporation, 1997.
  63. Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J: Normative data for the Animal, Profession and Letter M Naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc 2006;12:80–89.
  64. Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y: Formal and semantic lexical evocation in normal subjects: performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 1990;90:207–217.
  65. Novelli G, Papagno C, Capitani E, Laiacona M, Vallar G, Cappa S: Three clinical tests for the assessment of lexical retrieval and production: norms from 320 normal subjects. Arch Psicol Neurol Psichiatr 1986;47:477–506.
  66. Benton A, Hamsher L, Sivan K: Multilingual Aphasia Examination. Iowa City, AJA Associates, 1983.
  67. Reitan R: Validity of the Trail Making Test as an indication of organic brain damage. Percept Motor Skill 1958;8:271–276.

    External Resources

  68. Rey A: L’examen psychologie dans les cas d’encephalopathie traumatique. Arch Psychol 1941;28:286–340.
  69. Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A: Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci 2002;22:443–447.
  70. Coughlan AK, Hollows SE: The Adult Memory and Information Processing Battery (AMIPB). Leeds, Psychology Department of St James Hospital, 1985.
  71. Warrington E, James M: The Visual Object and Space Perception Battery. London, Harcourt Assessment, 1991.
  72. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–2388.
  73. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R: Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007;6:501–512.
  74. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA: A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204–1215.

 goto top of outline Author Contacts

Pieter Jelle Visser
Department of Psychiatry and Neuropsychology, University of Maastricht
PO Box 616
NL–6200 MD Maastricht (The Netherlands)
Tel. +31 20 617 1721, Fax +31 842 134 161, E-Mail

 goto top of outline Article Information

Received: January 23, 2008
Accepted: March 2, 2008
Published online: June 2, 2008
Number of Print Pages : 12
Number of Figures : 0, Number of Tables : 5, Number of References : 74

 goto top of outline Publication Details


Vol. 30, No. 4, Year 2008 (Cover Date: June 2008)

Journal Editor: Feigin V.L. (Auckland)
ISSN: 0251–5350 (Print), eISSN: 1423–0208 (Online)

For additional information:

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.